Bayer buys into Arvinas protein degrader discovery platformBayer is paying $17.5 million upfront to US biotech Arvinas, tapping into a protein-targeting platform to seek new Share XBayer buys into Arvinas protein degrader discovery platformhttps://pharmaphorum.com/news/bayer-buys-into-arvinas-protein-degrader-discovery-platform/
Bayer’s Aliqopa gets speedy review for marginal zone lymphomaThe FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) Share XBayer’s Aliqopa gets speedy review for marginal zone lymphomahttps://pharmaphorum.com/news/bayers-aliqopa-gets-speedy-review-for-marginal-zone-lymphoma/
Digital therapeutics start-ups need patience as well as patientsAn entirely new category of medicine is emerging, and a new wave of digital therapeutics start-ups is joining Share XDigital therapeutics start-ups need patience as well as patientshttps://pharmaphorum.com/views-analysis-digital/bayer-g4a-digital-therapeutics-startups/
FDA approves Regeneron’s Eylea for diabetic retinopathyRegeneron’s Eylea injection has been approved in the US for diabetic retinopathy, to treat all stages of the Share XFDA approves Regeneron’s Eylea for diabetic retinopathyhttps://pharmaphorum.com/news/fda-approves-regenerons-eylea-for-diabetic-retinopathy/
The sky’s the limit for the right digital health start-upsWhat started out six years ago as a local ‘passion project’ for Bayer to collaborate with Berlin’s digital Share XThe sky’s the limit for the right digital health start-upshttps://pharmaphorum.com/views-analysis-digital/bayer-g4a-digital-health-startups/
Novartis files potential blockbuster eye drug with FDANovartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough Share XNovartis files potential blockbuster eye drug with FDAhttps://pharmaphorum.com/news/novartis-files-potential-blockbuster-eye-drug/
Fusion raises $105m for radiopharmaceutical trialsRadiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to Share XFusion raises $105m for radiopharmaceutical trialshttps://pharmaphorum.com/news/fusion-raises-105m-towards-radiopharmaceutical-trials/
Bayer and J&J settle Xarelto lawsuits in USBayer and Johnson & Johnson have agreed to settle more than 25,000 US lawsuits worth more than $775 Share XBayer and J&J settle Xarelto lawsuits in UShttps://pharmaphorum.com/news/bayer-and-jj-settle-xarelto-lawsuits-in-us/
Bayer files prostate cancer drug darolutamide with EU regulatorsAfter filings in the US and Japan, Bayer has submitted data to European regulators for its prostate cancer Share XBayer files prostate cancer drug darolutamide with EU regulatorshttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-with-eu-regulators/
